Skip to main content
. Author manuscript; available in PMC: 2013 Mar 27.
Published in final edited form as: ACS Nano. 2012 Feb 16;6(3):2497–2505. doi: 10.1021/nn204885f

Figure 1.

Figure 1

Development of Cet/PTX/PEG-HCCs. A) PEG-HCCs have carbon cores approximately 40 nm × 1 nm functionalized with various oxygen containing functional groups (note that only one each of several representative groups are shown). PEG is conjugated to the core via an amide bond. By simple mixing protocols, the PEG-HCCs can be loaded with PTX and wrapped with Cet. B) Administering PEG-HCCs weekly to mice for 10 weeks results in no detectable toxicity, represented here by an image (100×) of the liver from a mouse treated for 10 weeks. The edge length of the image is 200 µm. The arrows mark the darker spots that likely indicate the presence of trace PEG-HCC aggregates.. C) PTX/PEG-HCCs have efficacy equivalent to Taxol® (PTX/Cremophor) for treating a murine orthotopic model of head and neck cancer. The arrows indicate the time-points of delivered treatment. D) When PTX/PEG-HCCs are functionalized with Cet, they target the delivery of PTX to EGFR+ cells in vitro. * p < 0.05.